XH-07|CAS|DC Chemicals

Cas No.:
Chemical Name:	XH-07
Synonyms:	XH07;XH 07
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC67984	L31(Lipid 31)	L31 is identified as a novel, proprietary ionizable cationic lipid that serves as the critical functional component within lipid nanoparticles (LNPs) engineered for CRISPR/Cas9 genome editing in head and neck squamous cell carcinoma (HNSCC). It was selected from a screened library of lipids for its superior performance. LNPs formulated with L31 exhibited excellent physicochemical properties, including a uniform size of 80-100 nm, low polydispersity, and high encapsulation efficiency (>85%) for both Cas9 mRNA and sgRNA. In vitro, L31-based LNPs demonstrated outstanding therapeutic efficacy, achieving approximately 68% gene editing of the oncogene SOX2 and an 88% reduction in cancer cell viability.For in vivo applications, L31-LNPs were further functionalized with anti-EGFR antibodies using the ASSET linker strategy to create targeted nanoparticles (tLNPs). This modification enhanced specific uptake by tumor cells. In a xenograft mouse model, intratumoral injection of these targeted L31-cLNPs co-encapsulating Cas9 mRNA and sgSOX2 led to potent tumor growth inhibition (90%) and a significant increase in survival, with tumor disappearance observed in half of the treated mice. In conclusion, L31 is a highly efficient ionizable lipid that forms the foundation of a potent targeted LNP platform for precise CRISPR-based cancer therapy against solid tumors.
DC67983	XH-07	XH-07 is an innovative ionizable cationic lipid that forms the backbone of the JCXH-211 lipid nanoparticle (LNP) delivery system. This complex is engineered to encapsulate and deliver self-replicating RNA (srRNA) encoding interleukin-12 (IL-12), a potent immunostimulatory cytokine. The LNP formulation featuring XH-07 exhibits optimal physicochemical properties, such as a mean particle size of approximately 82.12 nm with low polydispersity, and a near-neutral zeta potential around -3.181 mV, which facilitates stable circulation and efficient cellular uptake upon intravenous administration. Upon delivery, the srRNA leverages the host cell's machinery to produce sustained levels of IL-12p70, as demonstrated in B16F10 tumor-bearing mice, where a single dose led to peak cytokine production in sera and tumors. This induced IL-12 expression activates T cells and NK cells, generating a robust antitumor response. In murine models of melanoma and breast cancer, JCXH-211 monotherapy resulted in significant tumor regression and complete responses in some subjects, and it synergized with anti-PD-1 therapy to enhance efficacy. Importantly, the safety profile was acceptable, with transient liver enzyme elevations in mice that normalized quickly, and no significant adverse events in cynomolgus monkeys after repeated dosing, as evidenced by stable clinical observations and pathology tests. Thus, XH-07 is pivotal for enabling the safe and effective delivery of IL-12 encoding RNA, positioning JCXH-211 as a promising cancer immunotherapy.